Skip to main content
Premium Trial:

Request an Annual Quote

Berry Oncology Raises $99.2M in Series B1 Round

NEW YORK — Berry Oncology said on Thursday that it has closed a $99.2 million Series B1 round of financing.

The round was led by China Merchants Capital Management and included existing investors Qiming Venture Partners and Legend Capital, as well as new investors Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management, and Xiamen C&D Emerging Industry Equity Investment.

Berry Oncology, a subsidiary of Beijing-based Berry Genomics, said it has raised $309 million since its inception in 2017. The company offers cancer screening tests including Lai Si Ning, a next-generation sequencing-based assay for liver cancer, and maintains sites in Fuzhou and Beijing. It has been working with more than 700 hospitals across China and has provided genomic testing services for hundreds of thousands of cancer patients.

Earlier this year, Berry Oncology partnered with Alibaba Health, a division of Chinese technology firm Alibaba Group, to develop an early cancer screening and healthcare platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.